thalassemia
Vertex Gains Rights to Orna Therapeutics' Drug Delivery Tech in $1.07B Deal
Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.
Editas Medicine Lays off 65 Percent of Workforce; Drops Sickle Cell, TDT Candidate Reni-Cel
Editas, which was unable to identify a development or licensing partner for reni-cel, is focusing its resources on its in vivo pipeline.
Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on investigational candidates.
Vertex Pharmaceuticals Sues HHS, OIG Over Legality of Fertility Preservation Program
The firm is asking a court to determine that its program to pay for fertility treatments for patients on Casgevy doesn't violate anti-kickback and inducement laws.
Vertex CRISPR Therapy Casgevy Gets Conditional Marketing Authorization in EU
The EC's authorization for the sickle cell and transfusion-dependent beta thalassemia treatment follows marketing approvals in the US and UK.